Over the past 12 months, 9 insiders at Apellis Pharmaceuticals, Inc. filed 41 open-market SEC Form 4 transactions on APLS: 0 purchases worth $0 and 41 sales worth $13.7M. Insiders have been net sellers over this period. The most recent filing was on Feb 11, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 11, 26 | Mark Jeffrey DelongChief Business & Strat Officer | SELL | 368 | $22.15 | $8K |
| Jan 22, 26 | Caroline BaumalChief Medical Officer | SELL | 2.8K | $21.77 | $61K |
| Jan 22, 26 | James George ChopasVP/Chief Accounting Officer | SELL | 2.1K | $21.77 | $45K |
| Jan 22, 26 | Mark Jeffrey DelongChief Business & Strat Officer | SELL | 3.4K | $21.77 | $73K |
| Jan 22, 26 | Pascal DeschateletsChief Scientific Officer | SELL | 5.9K | $21.77 | $129K |
| Jan 22, 26 | Cedric FrancoisChief Executive Officer | SELL | 27.2K | $21.77 | $592K |
| Jan 22, 26 | Nur NicholsonChief Technical Officer | SELL | 7.7K | $21.77 | $168K |
| Jan 22, 26 | Timothy Eugene SullivanChief Financial Officer | SELL | 10.3K | $21.77 | $224K |
| Jan 22, 26 | David O. WatsonGeneral Counsel | SELL | 7.8K | $21.77 | $171K |
| Jan 20, 26 | Caroline BaumalChief Medical Officer | SELL | 1.9K | $19.79 | $37K |
| Jan 20, 26 | James George ChopasVP/Chief Accounting Officer | SELL | 726 | $19.79 | $14K |
| Jan 20, 26 | Mark Jeffrey DelongChief Business & Strat Officer | SELL | 1.3K | $19.79 | $26K |
| Jan 20, 26 | Pascal DeschateletsChief Scientific Officer | SELL | 909 | $19.79 | $18K |
| Jan 20, 26 | Cedric FrancoisChief Executive Officer | SELL | 8.2K | $19.79 | $162K |
| Jan 20, 26 | Nur NicholsonChief Technical Officer | SELL | 2.2K | $19.79 | $44K |
| Jan 20, 26 | Timothy Eugene SullivanChief Financial Officer | SELL | 2.9K | $19.79 | $57K |
| Jan 20, 26 | David O. WatsonGeneral Counsel | SELL | 2.5K | $19.79 | $49K |
| Jan 13, 26 | James George ChopasVP/Chief Accounting Officer | SELL | 873 | $22.19 | $19K |
| Jan 13, 26 | Mark Jeffrey DelongChief Business & Strat Officer | SELL | 1.8K | $22.19 | $39K |
| Jan 13, 26 | Pascal DeschateletsChief Scientific Officer | SELL | 2.3K | $22.19 | $51K |
| Jan 13, 26 | Cedric FrancoisChief Executive Officer | SELL | 10.2K | $22.19 | $226K |
| Jan 13, 26 | Nur NicholsonChief Technical Officer | SELL | 2.6K | $22.19 | $58K |
| Jan 13, 26 | Timothy Eugene SullivanChief Financial Officer | SELL | 3.9K | $22.19 | $86K |
| Jan 13, 26 | David O. WatsonGeneral Counsel | SELL | 5.8K | $22.19 | $128K |
| Jan 5, 26 | Caroline BaumalChief Medical Officer | SELL | 3.0K | $25.53 | $77K |
| Dec 16, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $24.49 | $122K |
| Nov 17, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $20.06 | $100K |
| Oct 21, 25 | Timothy Eugene SullivanChief Financial Officer | SELL | 10.0K | $28.03 | $280K |
| Oct 16, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $25.22 | $126K |
| Oct 10, 25 | A. Sinclair DunlopDirector | SELL | 31.1K | $23.72 | $738K |
| Sep 30, 25 | A. Sinclair DunlopDirector | SELL | 31.1K | $22.58 | $702K |
| Sep 19, 25 | A. Sinclair DunlopDirector | SELL | 31.1K | $22.95 | $714K |
| Sep 16, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $24.34 | $122K |
| Sep 15, 25 | James George ChopasVP/Chief Accounting Officer | SELL | 189 | $24.19 | $5K |
| Sep 10, 25 | David O. WatsonGeneral Counsel | SELL | 20.0K | $26.17 | $523K |
| Sep 8, 25 | Timothy Eugene SullivanChief Financial Officer | SELL | 32.7K | $27.86 | $912K |
| Sep 2, 25 | James George ChopasVP/Chief Accounting Officer | SELL | 548 | $28.08 | $15K |
| Aug 28, 25 | Cedric FrancoisChief Executive Officer | SELL | 50.0K | $28.39 | $1.4M |
| Aug 27, 25 | Cedric FrancoisChief Executive Officer | SELL | 175.0K | $28.19 | $4.9M |
| Aug 18, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $27.80 | $139K |
| Jul 17, 25 | Cedric FrancoisChief Executive Officer | SELL | 19.7K | $20.21 | $399K |
| Jul 16, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $19.55 | $98K |
| Jul 15, 25 | Cedric FrancoisChief Executive Officer | SELL | 1.9K | $20.09 | $38K |
| Jul 14, 25 | Cedric FrancoisChief Executive Officer | SELL | 137.5K | $20.19 | $2.8M |
| Jun 16, 25 | David O. WatsonGeneral Counsel | SELL | 5.0K | $18.77 | $94K |
| Mar 17, 25 | James George ChopasVP/Chief Accounting Officer | SELL | 183 | $24.82 | $5K |
| Mar 5, 25 | David O. WatsonGeneral Counsel | SELL | 5.6K | $25.10 | $140K |
| Feb 11, 25 | Mark Jeffrey DelongChief Business & Strat Officer | SELL | 363 | $28.54 | $10K |
| Jan 29, 25 | Mark Jeffrey DelongChief Business & Strat Officer | SELL | 365 | $29.52 | $11K |
| Jan 29, 25 | Pascal DeschateletsChief Scientific Officer | SELL | 826 | $29.52 | $24K |
Over the past 12 months, insiders at Apellis Pharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 41 sales worth $13.7M on APLS, which makes them net sellers over the period. The most recent Form 4 was filed on Feb 11, 26.
9 different insiders at Apellis Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on APLS over the last 12 months.
InsiderTape plots every APLS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Apellis Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →